Investing News NetworkYour trusted source for investing success
Helium Evolution
Integrated Cyber Solutions
Soma Gold Corp.
Purpose Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
Sorrento Therapeutics (NASDAQ:SRNE) announced today that it acquired the Sofusa lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, particularly, the immune checkpoint inhibitors (such as anti-PD-1, CTLA4, CD47 antibodies) and other I-O antibodies. As quoted in the press release: Pioneered by inventor Dr. Russell F. Ross and the innovation team at Kimberly-Clark, the Sofusa …
Sorrento Therapeutics (NASDAQ:SRNE) announced today that it acquired the Sofusa lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, particularly, the immune checkpoint inhibitors (such as anti-PD-1, CTLA4, CD47 antibodies) and other I-O antibodies.
As quoted in the press release:
Pioneered by inventor Dr. Russell F. Ross and the innovation team at Kimberly-Clark, the Sofusa technology consists of proprietary nano-structured microneedles designed to access the lymphatic capillaries just below the epidermis. In a recent Phase I human study, the Sofusa system has successfully demonstrated the ability to precisely tune the pharmacokinetic profile of sumatriptan to give both rapid onset and an extended treatment duration for the acute treatment of migraine.
“Sofusa technology allows pharmacological targeting of the lymphatics allowing new treatment strategies for cancer and chronic inflammatory conditions,” said Dr. Eva Sevick-Muraca, Ph.D., Professor and the Nancy and Rich Kinder Distinguished Chair of Cardiovascular Disease Research at the University of Texas Health Science Center’s Institute of Molecular Medicine (IMM). She is a biomedical engineer who has pioneered lymphatic imaging in humans and preclinical models of human disease and has been an advisor to Sofusa. Recently, her group presented preclinical work at AACR delivering an anti-CTLA4 mAb using the Sofusa device in a mouse model of metastatic breast cancer1.
Outlook Reports
Featured Pharmaceutical Investing Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2041.61 | +26.38 | |
Silver | 25.03 | +0.36 | |
Copper | 3.84 | +0.04 | |
Oil | 76.37 | +1.51 | |
Heating Oil | 2.80 | +0.05 | |
Natural Gas | 2.69 | -0.11 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.